SHANGHAI, April 17,
2024 /PRNewswire/ -- On April
17, 2024, Henlius (2696.HK) released its 2023
Environmental, Social and Governance (ESG) report (hereinafter
referred to as "ESG report" or "report"). The report
comprehensively discloses the Company's initiatives and
achievements in promoting is sustainability management strategies
in 2023 from five frontiers, namely product, talent, environment,
society and corporate governance. It is the fifth ESG-related
report released by Henlius.
Product: Affordable and Accessible for Value Creation
With patient-centricity in mind, Henlius focuses on unmet
clinical needs, and continuously translates innovative R&D
results into clinical applications. It drives social impact by
staying committed to making high-quality biologics affordable and
accessible to more patients around the world. Currently, 5 products
have been launched in China, 2 in
global markets, reaching over 40 countries and regions in
Asia, Europe, Latin
America and Oceania, and benefiting over 580,000 patients.
Henlius expands product global footprint by partnering with
international first-class biopharmaceutical companies, on 8
products including HANLIKANG (rituximab), HANQUYOU (trastuzumab,
trade name in Europe: Zercepac®)
and HANSIZHUANG (serplulimab), to penetrate mainstream markets as
well as emerging markets. Its core product HANQUYOU has been
approved in countries and regions including China, the United
Kingdom, France,
Germany, Argentina, Brazil, becoming the Chinese biosimilar with
the most approvals for marketing in countries and regions.
HANSIZHUANG is the world's first PD-1 mAb for the treatment of
small cell lung cancer (SCLC), which has been approved in
China and Indonesia.
Henlius actively explores multi-level medical coverage by means
of national health insurance entry, city-customized commercial
health insurance, patient assistance program, among others. It
actively expands sales channels, covering 31 provinces,
municipalities and autonomous regions to advance product
affordability and accessibility. Currently, HANQUYOU, HANLIKANG,
HANBEITAI (bevacizumab) and HANDAYUAN (adalimumab) have been
successively included into China's
National Reimbursement Drug List (NRDL). The innovative product
HANSIZHUANG has been included into 80 provincial/city-customized
commercial medical insurance (Huiminbao). Meanwhile, Henlius has
been providing HANSIZHUANG for free in a patient assistance
program, putting the effective therapy within the reach of more
patients in a timely manner.
Henlius eyes unmet clinical needs and puts innovative R&D
high on priority by establishing a high-quality and diversified
pipeline, with over 50 molecules covered. In 2023, Henlius
continued advancing R&D agenda, with a total of 11 products
making progress in R&D, and more than 30 clinical trials in
full swing in China, the U.S., the
European Union (EU), Australia and
other countries and regions. Moreover, Henlius is actively
exploring novel targets and mechanisms, constantly expanding into
more disease areas and molecular types, so as to accelerate the
development of innovative medicines to address complex diseases.
Currently, four orphan drugs and rare disease drugs are in clinical
stage for the treatment of indications including SCLC, LCH/ECD,
ALS, and idiopathic pulmonary fibrosis.
Henlius continues building a high-quality global supply system.
It has established manufacturing sites and quality management
systems conforming to the highest quality standards in China, the EU and the U.S. The two sites,
Xuhui Facility and Songjiang First Plant, both certificated by
China and the EU GMP, have a total
commercial capacity of 48,000 liters to ensure stable supply to
markets in China, Europe, Southeast
Asia and Latin America. In
2023, the Company's manufacturing sites and quality management
systems passed or accepted the on-site GMP inspections by the
regulatory authorities from the U.S., the EU, PIC/S members
Brazil and Indonesia, laying a solid foundation for the
globalization of its products.
Talent: Gathering Talents and Growing Together
Henlius is committed to pooling talents and building a
development platform that facilitates shared growth with employees.
In 2023, Henlius was awarded by HR Asia "Best Companies To Work For
In Asia" for two years in a row. By respecting the employees' legal
rights and interests, the Company creates a respectful, open and
inclusive working environment. The Company attaches great
importance to talent development and has established a
multi-dimensional, full-coverage and differentiated systematic
employee training system through "Henlius Academy" online learning
platform. In 2023, the training investment at Henlius totaled
RMB 2.6163 million, with average
training hour per employee amounting to 77.61 hours. Meanwhile, the
Company carried out talent review and launched "Y Trail" Project to
further clarify talent development planning at each stage. Apart
from providing the above-mentioned rich internal resources, the
Company continued providing assistance for employees in
qualification certification and on-the-job continuing education,
with 178 employees obtaining qualification certification in
2023.
Environment: Green Development and Building Resilience
Together
Henlius has always been adhering to the environmental management
guidelines of "preventing environmental pollution and reducing
energy consumption", integrating the concept of green development
throughout production and operations processes. The Company
invested approximately RMB 6.2421
million in environmental protection in 2023. The Company
took an array of strategies and measures to follow and meet four
major environmental targets for GHG emission reduction, energy use,
water resource use and waste discharge reduction. It called for
resources recycling among employees with a focus on "green office
concept" and controlled the high energy consumption equipment to
facility GHG emission reduction; it enhanced water efficiency in
manufacturing operations and optimized technological process for
wastewater treatment; it strengthened the management of unorganized
emission of exhaust gas and tracked emission of toxic substances;
it optimized emission management with a stricter classification for
waste management and a vigorous promotion of waste recycling. In
addition, the Company regularly evaluates the impact of production
and operation on the environment, and reviews and optimizes
environmental management initiatives through annual internal and
external environmental audits.
Society: Staying True to Original Aspiration for a Better
Future
As an important part of the eco-value chain, Henlius works hand
in hand with upstream and downstream partners to promote the
development of the industry and build a better community. Henlius
strives to build a sustainable supply chain, continues optimizing
supply chain operation mechanism, and strengthens supply chain risk
management. In 2023, the Company continued exploring local sourcing
and maintained 44 local suppliers of key materials, resulting in a
decrease in procurement costs of approximately RMB 24.58 million. It also launched a procurement
management system platform in 2023 to facilitate full-process order
processing for procurement with higher quality and efficiency.
Henlius is committed to giving back to the community while
striving for high-quality sustainable development. In 2023, the
overall charity investment of Henlius totaled about RMB 45.185 million. The Company proposes the
"patient- centered" public welfare concept and carries out charity
projects such as "To Time to the Life– cancer patient care program"
and "Rural Medical Care Public Welfare Activity". These efforts are
designated to care for the physical and mental health of cancer
patients, raising public awareness on cancers. Since its launching
four years ago, "Rural Medical Care Public Welfare Activity" has
benefited more than 4,700 patients and 2,200 primary medical staff,
and in the program Henlius has made in-kind donation totaled
RMB 270,000 to support local village
clinics.
Corporate Governance: Upholding Corporate Governance
Compliance and Shouldering Responsibility
Henlius has established a sound corporate governance structure
to continuously enhance the effectiveness of the Board of Directors
in the management of the Company's strategies and operating
practices, and to effectively exercise its supervisory
responsibilities. The Company has established a sound four-tier ESG
management structure and formulated an ESG management strategy
model in line with the corporate development strategy. The ESG
governance mechanism turns maturer and functions well. In daily
operation, the Company upholds compliant operations from such
aspects as corporate behavior, anti-corruption, responsible
advertising and marketing, information security and intellectual
property management, and delivers various trainings to embed the
concept into the daily work. For example, it delivered
anti-corruption training for all of the board members and 101
sessions for all employees in 2023.
In the future, Henlius will continue intensifying ESG management
practices based on material issues, pair ESG management strategies
with business development, keep the patients in mind, and provide
more high-quality therapies for global patients in response to
patient needs and clinical values.
About Henlius
Henlius (2696.HK) is a global biopharmaceutical company with the
vision to offer high-quality, affordable, and innovative biologic
medicines for patients worldwide with a focus on oncology,
autoimmune diseases, and ophthalmic diseases. Up to date, 5
products have been launched in China, 2 have been approved for marketing in
overseas markets, 19 indications are approved worldwide, and 7
marketing applications have been accepted for review in
China, the U.S., and the EU,
respectively. Since its inception in 2010, Henlius has built an
integrated biopharmaceutical platform with core capabilities of
high-efficiency and innovation embedded throughout the whole
product life cycle including R&D, manufacturing and
commercialization. It has established global innovation centers and
Shanghai-based manufacturing
facilities in line with global Good Manufacturing Practice (GMP),
including Xuhui Facility and Songjiang First Plant, both
certificated by China and the EU
GMP.
Henlius has pro-actively built a diversified and high-quality
product pipeline covering over 50 molecules and has continued to
explore immuno-oncology combination therapies with proprietary
HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched
products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU
(trastuzumab for injection, trade name in Europe: Zercepac®), the first China-developed mAb biosimilar approved both
in China and Europe, HANDAYUAN (adalimumab) and HANBEITAI
(bevacizumab), the innovative product HANSIZHUANG has been approved
by the NMPA for the treatment of MSI-H solid tumours, squamous
non-small cell lung cancer (sqNSCLC) and extensive-stage small cell
lung cancer (ES-SCLC), and esophageal squamous cell carcinoma
(ESCC), making it the world's first anti-PD-1 mAb for the
first-line treatment of SCLC. What's more, Henlius has conducted
over 30 clinical studies for 16 products, expanding its presence in
major markets as well as emerging markets.
View original
content:https://www.prnewswire.com/news-releases/henlius-releases-2023-esg-report-pursuing-sustainable-development-with-patient-centricity-302119490.html
SOURCE Henlius